Zymo Melanoma Drug Shrinks Tumors
Luke Timmerman5/13/09
ZymoGenetics, the Seattle biotech company, said today that one of its experimental cancer drugs that it is seeking to outlicense showed an ability to shrink tumors in a clinical trial. Interim results from a trial of 24 patients with metastatic melanoma—a form of skin cancer that has spread through the body and is difficult to treat—found that seven patients on Zymo’s IL-21 had their tumors shrink by at least 25 percent, and eight people had their disease stabilize.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
